Theravance Biopharma Inc — Cash Flow (NASDAQ:TBPH) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Cash from operating activities -250.4 M-207.86 M-186.99 M-27 M-11.54 M238.54 M 238.54 M Cash from investing activities 10.72 M124.49 M1.15 B-32.7 M12.28 M-105.28 M -105.28 M Cash from financing activities 263.08 M91.86 M-758.81 M-198.93 M-2.5 M-3.25 M -3.25 M Free cash flow -257.02 M-211.26 M-187.56 M-29.48 M-11.87 M238.5 M 238.41 M

Nouvelles

TD Cowen relève l’objectif de cours de Theravance Biopharma sur fond de focus sur les flux de trésorerie

Theravance's Q4 Earnings and Revenues Miss Estimates

BTIG réitère sa recommandation d’achat sur Theravance Biopharma après des revenus supérieurs aux attentes

Le BPA de Theravance Biopharma a dépassé les attentes de 0,15$, le CA en dessous des prévisions

Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates

Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates

Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)

Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)

Oppenheimer dégrade Theravance Biopharma après l’échec de Phase 3

Oppenheimer downgrades Theravance Biopharma stock rating on Phase 3 miss

TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study

B.Riley abaisse la note de Theravance Biopharma après l’échec d’un essai